Drug Profile
Nacubactam - Fedora Pharmaceuticals/Roche
Alternative Names: FPI-1459; OP-0595; RG 6080; RO 7079901Latest Information Update: 28 Nov 2023
Price :
$50
*
At a glance
- Originator Fedora Pharmaceuticals
- Developer Meiji Seika Pharma; Roche
- Class Anti-infectives; Anti-inflammatories; Antibacterials; Azabicyclo compounds; Small molecules
- Mechanism of Action Beta lactamase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Bacterial infections; Pyelonephritis; Urinary tract infections
Most Recent Events
- 28 Nov 2023 No recent reports of development identified for phase-I development in Bacterial-infections(Combination therapy, In volunteers) in Japan (IV, Infusion)
- 27 Nov 2023 Antimicrobial data from preclinical studies in Bacterial infections presented at the IDWeek-2023 (IDW-2023)
- 30 Jun 2023 Phase-III clinical trials in Bacterial infections (Combination therapy) in Spain, Japan (IV) (EudraCT2021-001396-16) (NCT05905055)